LBA28 STAR: A randomised multi-stage phase II/III trial of standard first-line therapy (sunitinib or pazopanib) comparing temporary cessation with allowing continuation, in the treatment of locally advanced and/or metastatic renal Cancer (RCC)
- 1 September 2021
- journal article
- abstracts
- Published by Elsevier in Annals of Oncology
- Vol. 32, S1303-S1304
Abstract
No abstract availableKeywords
Funding Information
- Roche
- Eisai
- Pfizer
- AstraZeneca
- Astellas Pharma